Across TCGA pan-cancer cohorts, VEGFB Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VEGFB data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher VEGFB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VEGFB expression acts as an unfavorable survival marker.
SKCM and BLCA are the cancer types where VEGFB Mutation most reproducibly stratifies survival.